Ann. Méd. Vét., 2002, 146 (2), pp 123 - 130 Tiludronate in horses: tolerance and short-term effects on bone metabolismVARELA A., LEPAGE O.M., DOUCET M., MARCOUX M., GARNERO P.Abstract :
The purpose of this study was to evaluate intravenous tolerance of tiludronate in horses and its effects on bone metabolism. Five French Trotters received 1 mg/kg of tiludronate intravenously during 30 min. Complete physical examination was performed, blood calcium as well as renal and hepatic parameters were monitored before and after treatment. Bone metabolism was evaluated before and 24 hours after treatment by measuring biochemical bone formation markers, osteocalcin and bone alkaline phosphatase and bone resorption markers, CTX-MMP (Carboxy-terminal cross-linked telopeptide of type I collagen generated by matrix metalloproteases) and CTX-I (Carboxy-terminal cross-linking telopeptide of type I collagen). A slight non-significant increase in heart rate without dysrhythmia was noted at +30 min. and at +2h. A transient slight hypocalcaemia was present with or without increased heart rate, in all horses at +30 min. However, 6h-post treatment, all values had returned to normal. There were no changes in plasma creatinine or hepatic parameters during the study. No changes in formation marker concentrations were observed after treatment, neither in CTX-MMP concentrations. Twenty-four hours post tiludronate IV administration, CTX-I levels markedly decreased by an average 72.4% (p=0.0313 vs. baseline). In conclusion, slow intravenous administration of tiludronate was well tolerated in horses without any clinically relevant adverse effects. The drug induces a rapid and marked decrease in serum CTX-I, indicating an antiresorptive effect. Get the PDF Contact person : aurore.varela@umontreal.ca |